Clinical Trial Update: TETRAM 2. Treatment With Erythropoetin in Patients With Spinal Trauma With Neurological Deficit, Maximum Tolerated Dose Study [Phase 1]

View source ↗

Summary

A Phase 1 study of erythropoietin for spinal cord injury with neurological deficit has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Cord Injury

Drugs mentioned

• Erythropoietin (erythropoietin)

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Spinal Trauma With Neurological Deficit | Phase 1 | Status: WITHDRAWN